Nabriva Therapeutics (NBRV) stock price, revenue, and financials

Nabriva Therapeutics market cap is $50.1 m, and annual revenue was $5.03 m in FY 2020

$50.1 M

NBRV Mkt cap, 11-Jun-2021

$2.5 M

Nabriva Therapeutics Revenue Q1, 2021
Nabriva Therapeutics Gross profit (Q1, 2021)2.5 M
Nabriva Therapeutics Gross profit margin (Q1, 2021), %97.5%
Nabriva Therapeutics Net income (Q1, 2021)-14 M
Nabriva Therapeutics EBIT (Q1, 2021)-13.4 M
Nabriva Therapeutics Cash, 31-Mar-202154.8 M
Nabriva Therapeutics EV3.1 M

Nabriva Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

32.8m86.8m102.0m86.0m41.4m

Accounts Receivable

2.7m3.9m

Prepaid Expenses

1.2m1.6m1.2m1.2m5.9m

Inventories

682.0k5.8m

Current Assets

90.6m93.8m108.8m91.2m57.2m

PP&E

519.0k1.3m1.1m2.5m768.0k

Total Assets

93.2m95.8m110.4m94.1m58.4m

Accounts Payable

2.6m5.1m3.3m4.7m2.9m

Short-term debt

2.0m

Current Liabilities

15.9m13.3m17.8m16.6m18.5m

Long-term debt

232.0k23.7m34.5m5.7m

Non-Current Liabilities

435.0k24.0m36.2m6.8m

Total Debt

232.0k23.7m34.5m7.7m

Total Liabilities

16.0m13.7m41.8m52.8m25.3m

Common Stock

2.9m670.0k945.0k211.0k

Additional Paid-in Capital

279.1m360.9m461.9m517.0m579.1m

Retained Earnings

(204.8m)(279.2m)(394.0m)(476.7m)(546.2m)

Total Equity

77.3m82.1m68.6m41.3m33.1m

Debt to Equity Ratio

0 x0.3 x

Debt to Assets Ratio

0 x0.2 x

Financial Leverage

1.2 x1.2 x1.6 x2.3 x1.8 x

Quarterly

USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

27.2m20.1m112.2m89.4m75.3m100.3m91.0m58.7m78.1m26.9m49.7m41.1m54.8m

Accounts Receivable

6.5m3.5m3.2m3.4m4.2m

Prepaid Expenses

903.0k1.4m1.5m1.0m1.2m1.2m973.0k1.4m1.2m2.9m3.9m3.8m10.2m

Inventories

162.0k4.2m5.2m5.8m9.0m

Current Assets

76.6m63.2m117.9m98.5m84.9m110.7m100.5m80.1m86.4m38.2m62.4m54.3m78.4m

PP&E

490.0k1.4m1.4m1.4m1.3m1.2m3.0m2.8m2.7m2.3m2.2m2.0m521.0k

Total Assets

78.9m67.4m119.9m100.5m86.8m112.4m104.0m83.6m90.1m41.0m65.1m56.8m79.4m

Accounts Payable

4.3m8.3m5.3m3.8m2.9m4.8m7.6m2.9m3.2m2.0m2.6m2.0m3.6m

Short-term debt

2.6m

Current Liabilities

15.9m16.8m16.3m11.4m11.3m15.1m18.1m14.1m14.9m12.0m11.0m11.0m18.3m

Long-term debt

203.0k218.0k227.0k411.0k592.0k710.0k23.9m24.3m34.2m7.4m7.5m7.6m5.2m

Non-Current Liabilities

337.0k364.0k425.0k636.0k828.0k954.0k25.8m26.1m36.0m9.1m9.6m9.6m6.1m

Total Debt

203.0k218.0k227.0k411.0k592.0k710.0k23.9m24.3m34.2m7.4m7.5m7.6m7.8m

Total Liabilities

16.2m17.1m16.8m12.0m12.1m16.0m43.9m40.2m50.9m21.1m20.6m20.5m24.4m

Common Stock

2.9m402.0k410.0k665.0k713.0k729.0k780.0k951.0k1.4m1.5m354.0k

Additional Paid-in Capital

279.8m284.0m359.7m380.6m384.6m458.9m473.6m478.6m492.1m518.9m558.4m563.1m614.8m

Retained Earnings

(220.1m)(234.7m)(256.9m)(292.5m)(310.3m)(363.2m)(414.2m)(435.9m)(453.7m)(500.0m)(515.4m)(528.4m)(560.2m)

Total Equity

62.7m50.3m103.1m88.4m74.7m96.4m60.1m43.4m39.2m19.9m44.5m36.2m55.0m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0.4 x0.6 x0.9 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0.2 x0.3 x0.4 x

Financial Leverage

1.3 x1.3 x1.2 x1.1 x1.2 x1.2 x1.7 x1.9 x2.3 x2.1 x1.5 x1.6 x1.4 x

Nabriva Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(54.9m)(74.4m)(114.8m)(82.8m)(69.5m)

Depreciation and Amortization

233.0k432.0k510.0k396.0k417.0k

Accounts Receivable

(1.9m)(223.0k)1.1m

Inventories

(682.0k)(5.1m)

Accounts Payable

(383.0k)2.6m(3.0m)1.3m(1.8m)

Cash From Operating Activities

(49.3m)(69.3m)(72.7m)(71.9m)(71.3m)

Purchases of PP&E

(603.0k)(1.2m)(229.0k)(61.0k)(113.0k)

Cash From Investing Activities

23.4m49.7m(4.6m)331.0k(274.0k)

Cash From Financing Activities

22.3m72.2m92.9m56.1m26.9m

Net Change in Cash

(3.7m)54.0m15.2m(15.6m)(44.8m)

Interest Paid

1.0k1.4m

Income Taxes Paid

5.0k

Nabriva Therapeutics Ratios

USDFY, 2016

Financial Leverage

1.2 x